Related Experiment Videos
Molecular therapies for viral hepatitis
Chandan Guha1, Shalin J Shah, Siddhartha S Ghosh
1Department of Radiation Oncology, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY 10461, USA.
Summary
Novel molecular and gene therapies are crucial for treating hepatitis B (HBV) and C (HCV) infections due to current treatment inefficiencies. Research focuses on reducing viral load and boosting immune responses for better viral hepatitis outcomes.
Area of Science:
- Hepatology
- Virology
- Gene Therapy
Background:
- Current treatments for hepatitis B virus (HBV) and hepatitis C virus (HCV) are insufficient, highlighting the urgent need for novel therapeutic strategies.
- The significant global disease burden necessitates the development of advanced therapies, including vaccines for HCV and molecular treatments for both HBV and HCV.
Purpose of the Study:
- To review current and emerging molecular and gene therapy approaches for treating HBV and HCV infections.
- To explore the potential of DNA-based vaccination and gene transfer vectors for the prevention and treatment of viral hepatitis.
Main Methods:
- Investigating molecular therapies targeting viral life cycles, including antisense RNAs, ribozymes, and dominant-negative proteins.
- Examining DNA-based vaccination strategies and the development of non-viral and viral vectors for liver-directed gene transfer.
Main Results:
- Antiviral approaches aim to reduce viral load by interfering with viral replication or by stimulating an immune response against viral epitopes.
- Ongoing advancements in vector systems, though no ideal vector exists, show promise for effective gene therapy applications.
Conclusions:
- Gene therapy holds significant potential for the future prevention and treatment of viral hepatitis.
- Continued innovation in vector development and molecular targeting is key to overcoming the challenges posed by HBV and HCV infections.